$ICPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERCEPT PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INTERCEPT PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 ... 13 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Payment of Exercise | F | 123.92 | 150 | 18,588 | 7,035 | 7.2 K to 7 K (-2.09 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Payment of Exercise | F | 123.92 | 259 | 32,095 | 7,185 | 7.4 K to 7.2 K (-3.48 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President, Internat ... | Payment of Exercise | F | 123.92 | 530 | 65,678 | 17,814 | 18.3 K to 17.8 K (-2.89 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President, Internat ... | Payment of Exercise | F | 123.92 | 388 | 48,081 | 18,344 | 18.7 K to 18.3 K (-2.07 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Option Exercise | M | 21.50 | 100 | 2,150 | 30,084 | |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Payment of Exercise | F | 123.92 | 1,166 | 144,491 | 466,829 | 468 K to 466.8 K (-0.25 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Payment of Exercise | F | 123.92 | 1,131 | 140,154 | 467,995 | 469.1 K to 468 K (-0.24 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Sell | S | 125.00 | 100 | 12,500 | 469,126 | 469.2 K to 469.1 K (-0.02 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Buy | M | 21.50 | 100 | 2,150 | 469,226 | 469.1 K to 469.2 K (+0.02 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Payment of Exercise | F | 123.92 | 809 | 100,251 | 21,080 | 21.9 K to 21.1 K (-3.70 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 123.92 | 54 | 6,692 | 13,760 | 13.8 K to 13.8 K (-0.39 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 123.92 | 364 | 45,107 | 13,814 | 14.2 K to 13.8 K (-2.57 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Sell | S | 117.16 | 259 | 30,344 | 10,580 | 10.8 K to 10.6 K (-2.39 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 123.92 | 106 | 13,136 | 10,839 | 10.9 K to 10.8 K (-0.97 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 123.92 | 323 | 40,026 | 10,945 | 11.3 K to 10.9 K (-2.87 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Option Exercise | M | 54.63 | 262 | 14,313 | 20,779 | |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Payment of Exercise | F | 123.92 | 349 | 43,248 | 18,373 | 18.7 K to 18.4 K (-1.86 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Sell | S | 125.00 | 262 | 32,750 | 18,722 | 19 K to 18.7 K (-1.38 %) |
Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Buy | M | 54.63 | 262 | 14,313 | 18,984 | 18.7 K to 19 K (+1.40 %) |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 58.74 | 54 | 3,172 | 2,883 | |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 59.12 | 416 | 24,594 | 17,692 | |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 123.24 | 1,581 | 194,842 | 14,178 | 15.8 K to 14.2 K (-10.03 %) |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 58.74 | 54 | 3,172 | 15,759 | 15.7 K to 15.8 K (+0.34 %) |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 59.12 | 416 | 24,594 | 15,705 | 15.3 K to 15.7 K (+2.72 %) |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Option Exercise | M | 21.50 | 417 | 8,966 | 30,184 | |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Sell | S | 125.00 | 417 | 52,125 | 469,126 | 469.5 K to 469.1 K (-0.09 %) |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Buy | M | 21.50 | 417 | 8,966 | 469,543 | 469.1 K to 469.5 K (+0.09 %) |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Option Exercise | M | 54.63 | 54 | 2,950 | 21,041 | |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Sell | S | 125.00 | 54 | 6,750 | 18,722 | 18.8 K to 18.7 K (-0.29 %) |
Dec 30 2019 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Buy | M | 54.63 | 54 | 2,950 | 18,776 | 18.7 K to 18.8 K (+0.29 %) |
Dec 20 2019 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Sell | S | 119.45 | 154 | 18,395 | 7,444 | 7.6 K to 7.4 K (-2.03 %) |
Dec 17 2019 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Payment of Exercise | F | 114.16 | 80 | 9,133 | 7,598 | 7.7 K to 7.6 K (-1.04 %) |
Dec 05 2019 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Option Exercise | M | 54.63 | 80 | 4,370 | 21,095 | |
Dec 05 2019 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Buy | M | 54.63 | 80 | 4,370 | 18,722 | 18.6 K to 18.7 K (+0.43 %) |
Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 58.74 | 52 | 3,054 | 2,937 | |
Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 59.12 | 875 | 51,730 | 18,108 | |
Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 109.16 | 357 | 38,970 | 15,289 | 15.6 K to 15.3 K (-2.28 %) |
Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 101.65 | 1,040 | 105,716 | 15,646 | 16.7 K to 15.6 K (-6.23 %) |
Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 58.74 | 52 | 3,054 | 16,686 | 16.6 K to 16.7 K (+0.31 %) |
Dec 02 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 59.12 | 875 | 51,730 | 16,634 | 15.8 K to 16.6 K (+5.55 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 58.74 | 106 | 6,226 | 2,989 | |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 59.12 | 4,267 | 252,265 | 18,983 | |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 58.74 | 105 | 6,168 | 3,095 | |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | M | 59.12 | 1,750 | 103,460 | 23,250 | |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 100.00 | 4,373 | 437,300 | 15,759 | 20.1 K to 15.8 K (-21.72 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 58.74 | 106 | 6,226 | 20,132 | 20 K to 20.1 K (+0.53 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 59.12 | 4,267 | 252,265 | 20,026 | 15.8 K to 20 K (+27.08 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 100.00 | 1,855 | 185,500 | 15,759 | 17.6 K to 15.8 K (-10.53 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 58.74 | 105 | 6,168 | 17,614 | 17.5 K to 17.6 K (+0.60 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Buy | M | 59.12 | 1,750 | 103,460 | 17,509 | 15.8 K to 17.5 K (+11.10 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Option Exercise | M | 21.50 | 15,557 | 334,476 | 30,601 | |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Option Exercise | M | 8.67 | 19,880 | 172,294 | 0 | |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Option Exercise | M | 8.67 | 14,524 | 125,875 | 19,880 | |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Option Exercise | M | 8.67 | 39 | 338 | 0 | |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Sell | S | 100.00 | 35,437 | 3,543,700 | 469,126 | 504.6 K to 469.1 K (-7.02 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Buy | M | 21.50 | 15,557 | 334,476 | 504,563 | 489 K to 504.6 K (+3.18 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Buy | M | 8.67 | 19,880 | 172,294 | 489,006 | 469.1 K to 489 K (+4.24 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Sell | S | 100.00 | 14,563 | 1,456,300 | 469,126 | 483.7 K to 469.1 K (-3.01 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Buy | M | 8.67 | 14,524 | 125,875 | 483,689 | 469.2 K to 483.7 K (+3.10 %) |
Nov 27 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Buy | M | 8.67 | 39 | 338 | 469,165 | 469.1 K to 469.2 K (+0.01 %) |
Nov 26 2019 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 88.89 | 460 | 40,889 | 31,812 | 32.3 K to 31.8 K (-1.43 %) |
Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 85.00 | 1,550 | 131,750 | 15,759 | 17.3 K to 15.8 K (-8.95 %) |
Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 85.00 | 1,550 | 131,750 | 15,759 | 17.3 K to 15.8 K (-8.95 %) |
Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Option Exercise | M | 53.41 | 8,325 | 444,638 | 26,475 | |
Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Option Exercise | M | 53.41 | 8,325 | 444,638 | 26,475 | |
Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Sell | S | 85.00 | 3,829 | 325,465 | 21,889 | 25.7 K to 21.9 K (-14.89 %) |
Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Sell | S | 85.00 | 3,829 | 325,465 | 21,889 | 25.7 K to 21.9 K (-14.89 %) |
Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Sell | S | 85.00 | 8,325 | 707,625 | 25,718 | 34 K to 25.7 K (-24.45 %) |
Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Sell | S | 85.00 | 8,325 | 707,625 | 25,718 | 34 K to 25.7 K (-24.45 %) |
Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Buy | M | 53.41 | 8,325 | 444,638 | 34,043 | 25.7 K to 34 K (+32.37 %) |
Nov 19 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Buy | M | 53.41 | 8,325 | 444,638 | 34,043 | 25.7 K to 34 K (+32.37 %) |
Nov 15 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Option Exercise | M | 53.41 | 500 | 26,705 | 34,800 | |
Nov 15 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Payment of Exercise | F | 83.92 | 711 | 59,667 | 25,718 | 26.4 K to 25.7 K (-2.69 %) |
Nov 15 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Sell | S | 85.00 | 500 | 42,500 | 26,429 | 26.9 K to 26.4 K (-1.86 %) |
Nov 15 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Buy | M | 53.41 | 500 | 26,705 | 26,929 | 26.4 K to 26.9 K (+1.89 %) |
Nov 15 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 85.00 | 946 | 80,410 | 17,309 | 18.3 K to 17.3 K (-5.18 %) |
Nov 14 2019 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Payment of Exercise | F | 83.02 | 319 | 26,483 | 18,642 | 19 K to 18.6 K (-1.68 %) |
Nov 12 2019 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 82.76 | 128 | 10,593 | 11,268 | 11.4 K to 11.3 K (-1.12 %) |
Oct 31 2019 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President, Internat ... | Sell | S | 75.00 | 595 | 44,625 | 18,732 | 19.3 K to 18.7 K (-3.08 %) |
Oct 25 2019 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Sell | S | 70.00 | 58 | 4,060 | 11,396 | 11.5 K to 11.4 K (-0.51 %) |
Oct 03 2019 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 65.87 | 92 | 6,060 | 11,454 | 11.5 K to 11.5 K (-0.80 %) |
Oct 03 2019 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 65.87 | 417 | 27,468 | 32,272 | 32.7 K to 32.3 K (-1.28 %) |
Oct 03 2019 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President, Internat ... | Payment of Exercise | F | 65.87 | 530 | 34,911 | 19,327 | 19.9 K to 19.3 K (-2.67 %) |
Oct 03 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 65.87 | 46 | 3,030 | 18,255 | 18.3 K to 18.3 K (-0.25 %) |
Oct 03 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Payment of Exercise | F | 65.87 | 1,547 | 101,901 | 469,126 | 470.7 K to 469.1 K (-0.33 %) |
Oct 03 2019 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Payment of Exercise | F | 65.87 | 267 | 17,587 | 16,747 | 17 K to 16.7 K (-1.57 %) |
Oct 03 2019 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Payment of Exercise | F | 65.87 | 626 | 41,235 | 26,067 | 26.7 K to 26.1 K (-2.35 %) |
Sep 18 2019 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Sell | S | 70.00 | 800 | 56,000 | 11,546 | 12.3 K to 11.5 K (-6.48 %) |
Aug 30 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | P | 60.32 | 5,207 | 314,086 | 403,688 | 398.5 K to 403.7 K (+1.31 %) |
Aug 29 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 60.50 | 357 | 21,599 | 18,301 | 18.7 K to 18.3 K (-1.91 %) |
Aug 29 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 60.50 | 357 | 21,599 | 18,301 | 18.7 K to 18.3 K (-1.91 %) |
Aug 27 2019 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 60.90 | 319 | 19,427 | 32,689 | 33 K to 32.7 K (-0.97 %) |
Aug 22 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Grant | A | 64.30 | 1,180 | 75,874 | 398,481 | 397.3 K to 398.5 K (+0.30 %) |
Aug 22 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Grant | A | 67.12 | 29,000 | 1,946,480 | 397,301 | 368.3 K to 397.3 K (+7.87 %) |
Aug 22 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Grant | A | 65.85 | 37,604 | 2,476,223 | 368,301 | 330.7 K to 368.3 K (+11.37 %) |
Aug 14 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Payment of Exercise | F | 66.03 | 689 | 45,495 | 26,429 | 27.1 K to 26.4 K (-2.54 %) |
Aug 14 2019 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Payment of Exercise | F | 65.89 | 319 | 21,019 | 18,961 | 19.3 K to 19 K (-1.65 %) |
Aug 09 2019 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 66.05 | 128 | 8,454 | 12,346 | 12.5 K to 12.3 K (-1.03 %) |
Jul 15 2019 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Payment of Exercise | F | 69.71 | 111 | 7,738 | 17,014 | 17.1 K to 17 K (-0.65 %) |
Jul 03 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 79.17 | 46 | 3,642 | 18,658 | 18.7 K to 18.7 K (-0.25 %) |
Jul 03 2019 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Payment of Exercise | F | 79.17 | 615 | 48,690 | 26,693 | 27.3 K to 26.7 K (-2.25 %) |
Jul 03 2019 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 79.17 | 92 | 7,284 | 12,474 | 12.6 K to 12.5 K (-0.73 %) |
Jul 03 2019 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 79.17 | 289 | 22,880 | 33,008 | 33.3 K to 33 K (-0.87 %) |
Jul 03 2019 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President, Internat ... | Sell | S | 78.66 | 595 | 46,803 | 19,857 | 20.5 K to 19.9 K (-2.91 %) |
Jul 03 2019 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President, Internat ... | Payment of Exercise | F | 79.17 | 530 | 41,960 | 20,452 | 21 K to 20.5 K (-2.53 %) |
Jul 03 2019 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Payment of Exercise | F | 79.17 | 1,548 | 122,555 | 470,673 | 472.2 K to 470.7 K (-0.33 %) |
Jul 03 2019 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Payment of Exercise | F | 79.17 | 268 | 21,218 | 17,125 | 17.4 K to 17.1 K (-1.54 %) |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | SBLENDORIO GLENN | Director | Option Exercise | A | 82.25 | 2,174 | 178,812 | 2,174 | |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | SBLENDORIO GLENN | Director | Grant | A | 0.00 | 1,570 | 0 | 7,086 | 5.5 K to 7.1 K (+28.46 %) |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | SANTINI GINO | Director | Option Exercise | A | 82.25 | 2,174 | 178,812 | 2,174 | |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | SANTINI GINO | Director | Grant | A | 0.00 | 1,570 | 0 | 7,284 | 5.7 K to 7.3 K (+27.48 %) |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | Miller-Rich Nancy | Director | Option Exercise | A | 82.25 | 2,174 | 178,812 | 2,174 | |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | Miller-Rich Nancy | Director | Grant | A | 0.00 | 1,570 | 0 | 5,943 | 4.4 K to 5.9 K (+35.90 %) |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | Gottesdiener Keith Michael | Director | Option Exercise | A | 82.25 | 2,174 | 178,812 | 2,174 | |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | Gottesdiener Keith Michael | Director | Grant | A | 0.00 | 1,570 | 0 | 8,358 | 6.8 K to 8.4 K (+23.13 %) |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | A | 82.25 | 2,174 | 178,812 | 2,174 | |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Grant | A | 0.00 | 1,570 | 0 | 19,433 | 17.9 K to 19.4 K (+8.79 %) |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | BRADBURY DANIEL | Director | Option Exercise | A | 82.25 | 2,174 | 178,812 | 2,174 | |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | BRADBURY DANIEL | Director | Grant | A | 0.00 | 1,570 | 0 | 7,187 | 5.6 K to 7.2 K (+27.95 %) |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | Benatti Luca | Director | Option Exercise | A | 82.25 | 2,174 | 178,812 | 2,174 | |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | Benatti Luca | Director | Grant | A | 0.00 | 1,570 | 0 | 9,126 | 7.6 K to 9.1 K (+20.78 %) |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | A | 82.25 | 2,174 | 178,812 | 2,174 | |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Grant | A | 0.00 | 1,570 | 0 | 21,526 | 20 K to 21.5 K (+7.87 %) |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | WELCH DANIEL G | Director | Option Exercise | A | 82.25 | 2,174 | 178,812 | 2,174 | |
Jun 21 2019 | ICPT | INTERCEPT PHARMACE ... | WELCH DANIEL G | Director | Grant | A | 0.00 | 1,570 | 0 | 6,465 | 4.9 K to 6.5 K (+32.07 %) |
May 29 2019 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 87.83 | 357 | 31,355 | 18,704 | 19.1 K to 18.7 K (-1.87 %) |
May 28 2019 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 85.51 | 460 | 39,335 | 33,297 | 33.8 K to 33.3 K (-1.36 %) |
May 22 2019 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 21.50 | 3,288 | 70,692 | 0 | |
May 22 2019 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 9.30 | 3,461 | 32,195 | 0 | |
May 22 2019 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 21.50 | 3,288 | 70,692 | 17,863 | 14.6 K to 17.9 K (+22.56 %) |
May 22 2019 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 9.30 | 3,461 | 32,195 | 14,575 | 11.1 K to 14.6 K (+31.14 %) |
May 14 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Grant | A | 83.50 | 119,760 | 9,999,960 | 330,697 | 210.9 K to 330.7 K (+56.78 %) |
May 14 2019 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Payment of Exercise | F | 86.66 | 319 | 27,645 | 19,280 | 19.6 K to 19.3 K (-1.63 %) |
May 14 2019 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Payment of Exercise | F | 83.73 | 711 | 59,532 | 27,118 | 27.8 K to 27.1 K (-2.55 %) |
May 14 2019 | ICPT | INTERCEPT PHARMACE ... | Benatti Luca | Director | Buy | P | 83.50 | 1,200 | 100,200 | 7,556 | 6.4 K to 7.6 K (+18.88 %) |
May 10 2019 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 87.57 | 128 | 11,209 | 12,566 | 12.7 K to 12.6 K (-1.01 %) |
May 03 2019 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | Chief Medical Offic ... | Option Exercise | M | 31.90 | 2,000 | 63,800 | 9,031 | |
May 03 2019 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | Chief Medical Offic ... | Sell | S | 86.28 | 2,000 | 172,560 | 39,499 | 41.5 K to 39.5 K (-4.82 %) |
May 03 2019 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | Chief Medical Offic ... | Buy | M | 31.90 | 2,000 | 63,800 | 41,499 | 39.5 K to 41.5 K (+5.06 %) |
Apr 29 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 31.90 | 1,001 | 31,932 | 979 | |
Apr 29 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 21.50 | 2,499 | 53,729 | 0 | |
Apr 29 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 31.90 | 1,001 | 31,932 | 19,956 | 19 K to 20 K (+5.28 %) |
Apr 29 2019 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 21.50 | 2,499 | 53,729 | 18,955 | 16.5 K to 19 K (+15.19 %) |
Apr 22 2019 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Option Exercise | M | 54.63 | 1,750 | 95,603 | 21,175 | |
Apr 22 2019 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Buy | M | 54.63 | 1,750 | 95,603 | 19,599 | 17.8 K to 19.6 K (+9.80 %) |
Apr 16 2019 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | Chief Medical Offic ... | Option Exercise | M | 31.90 | 2,000 | 63,800 | 11,031 | |
Apr 16 2019 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | Chief Medical Offic ... | Sell | S | 95.00 | 2,000 | 190,000 | 39,499 | 41.5 K to 39.5 K (-4.82 %) |
Apr 16 2019 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | Chief Medical Offic ... | Buy | M | 31.90 | 2,000 | 63,800 | 41,499 | 39.5 K to 41.5 K (+5.06 %) |
Apr 16 2019 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Payment of Exercise | F | 95.21 | 77 | 7,331 | 17,393 | 17.5 K to 17.4 K (-0.44 %) |
Apr 03 2019 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 111.50 | 289 | 32,224 | 33,757 | 34 K to 33.8 K (-0.85 %) |